BioCryst Pharmaceuticals, Inc. (BCRX)Â
Largest Insider Buys in Sector
BCRX Stock Price History Chart
BCRX Stock Performance
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Activity of BioCryst Pharmaceuticals, Inc.
Over the last 12 months, insiders at BioCryst Pharmaceuticals, Inc. have bought $1.05M and sold $176,191 worth of BioCryst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at BioCryst Pharmaceuticals, Inc. have bought $673,474 and sold $4.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thackray Helen M. (Chief R&D Officer) — $351,600. Doyle Anthony (Chief Financial Officer) — $202,191. Stonehouse Jon P (President & CEO) — $166,500.
The last purchase of 7,861 shares for transaction amount of $49,996 was made by LEVIN ALAN G (director) on 2024‑05‑30.
List of Insider Buy and Sell Transactions, BioCryst Pharmaceuticals, Inc.
| 2024-12-13 | Sale | director | 7,000 0.0034% | $7.54 | $52,780 | +0.53% | ||
| 2024-06-24 | Sale | director | 8,600 0.0042% | $6.32 | $54,352 | +21.53% | ||
| 2024-06-17 | Sale | director | 4,689 0.0021% | $6.00 | $28,134 | +21.96% | ||
| 2024-06-14 | Sale | director | 6,698 0.0031% | $6.11 | $40,925 | +23.26% | ||
| 2024-05-30 | director | 7,861 0.0037% | $6.36 | $49,996 | +15.22% | |||
| 2024-05-24 | director | 2,500 0.0012% | $6.40 | $16,000 | +23.00% | |||
| 2024-05-20 | director | 5,000 0.0025% | $6.38 | $31,900 | +22.96% | |||
| 2024-05-20 | director | 15,000 0.0074% | $6.25 | $93,750 | +22.96% | |||
| 2024-05-14 | Chief R&D Officer | 30,000 0.0159% | $5.86 | $175,800 | +40.56% | |||
| 2024-05-14 | Chief Financial Officer | 36,300 0.0183% | $5.57 | $202,191 | +40.56% | |||
| 2024-05-13 | President & CEO | 30,000 0.0143% | $5.55 | $166,500 | +33.33% | |||
| 2024-05-13 | Chief Commercial Officer | 30,000 0.0141% | $5.47 | $164,100 | +33.33% | |||
| 2024-05-13 | Chief Legal Officer | 5,000 0.0024% | $5.53 | $27,650 | +33.33% | |||
| 2024-05-13 | director | 21,940 0.0104% | $5.49 | $120,451 | +33.33% | |||
| 2023-06-15 | Sale | director | 4,000 0.0021% | $7.98 | $31,920 | -24.59% | ||
| 2023-06-14 | Sale | director | 12,866 0.0069% | $8.04 | $103,443 | -24.06% | ||
| 2023-04-03 | Sale | Chief R&D Officer | 7,000 0.0037% | $8.29 | $58,030 | -19.09% | ||
| 2023-02-01 | Sale | President & CEO | 100,000 0.0523% | $10.38 | $1.04M | -31.89% | ||
| 2022-12-15 | Sale | President & CEO | 14,100 0.0079% | $10.90 | $153,690 | -30.48% | ||
| 2022-12-15 | Sale | Chief Commercial Officer | 6,100 0.0034% | $10.90 | $66,490 | -30.48% |
Insider Historical Profitability
| Stonehouse Jon P | President & CEO | 1127770 0.5445% | $7.45 | 14 | 8 | +33.26% |
| Gayer Charles K | Chief Commercial Officer | 307533 0.1485% | $7.45 | 1 | 1 | |
| Barnes Alane P | Chief Legal Officer | 300762 0.1452% | $7.45 | 2 | 8 | +118.24% |
| Thackray Helen M. | Chief R&D Officer | 272139 0.1314% | $7.45 | 1 | 3 | |
| Doyle Anthony | Chief Financial Officer | 266744 0.1288% | $7.45 | 3 | 1 | +77.54% |
| Hutson Nancy J | director | 86638 0.0418% | $7.45 | 3 | 4 | +118.24% |
| MILANO VINCENT | director | 66997 0.0323% | $7.45 | 2 | 0 | +5.36% |
| HEGGIE THERESA | director | 52852 0.0255% | $7.45 | 1 | 1 | +118.24% |
| Galson Steven K | director | 51551 0.0249% | $7.45 | 1 | 0 | |
| LEVIN ALAN G | director | 44951 0.0217% | $7.45 | 1 | 0 | |
| SANDERS MACHELLE | director | 27742 0.0134% | $7.45 | 0 | 2 | |
| McKee Amy E | director | 27831 0.0134% | $7.45 | 0 | 1 | |
| ASELAGE STEVE | director | 2500 0.0012% | $7.45 | 4 | 0 | +52.14% |
| BAKER FELIX | 10 percent owner | 4832285 2.3329% | $7.45 | 1 | 0 | +60.41% |
| Baker Brothers Life Sciences Capital (GP), LLC | 10 percent owner | 3831534 1.8498% | $7.45 | 3 | 3 | +289.09% |
| BAKER BROS. ADVISORS LP | 10 percent owner | 1551387 0.749% | $7.45 | 11 | 3 | <0.0001% |
| Baker Biotech Capital (GP), LLC | 10 percent owner | 1522015 0.7348% | $7.45 | 3 | 3 | +289.09% |
| BVF PARTNERS L P/IL | Indirect Beneficial Owner | 1455900 0.7029% | $7.45 | 0 | 1 | |
| GORDON CARL L | director | 1100000 0.5311% | $7.45 | 0 | 1 | |
| SHERRILL JOSEPH H JR | director | 492000 0.2375% | $7.45 | 5 | 0 | +141.01% |
| Babu Yarlagadda S | Chief Discovery Officer | 298541 0.1441% | $7.45 | 1 | 14 | +118.24% |
| FEATHERINGILL WILLIAM W | director, 10 percent owner | 231538 0.1118% | $7.45 | 3 | 4 | <0.0001% |
| STAAB THOMAS R II | Senior Vice President and CFO | 125176 0.0604% | $7.45 | 0 | 46 | |
| 14159 capital (GP), LLC | 10 percent owner | 120828 0.0583% | $7.45 | 3 | 3 | +289.09% |
| Cohen Fred E | director | 119410 0.0576% | $7.45 | 0 | 1 | |
| Baker Bros. Capital (GP), LLC | 10 percent owner | 71997 0.0348% | $7.45 | 3 | 3 | +289.09% |
| BENNETT J CLAUDE | Chief Operating Officer | 65730 0.0317% | $7.45 | 2 | 5 | <0.0001% |
| BUGG CHARLES E | director | 62439 0.0301% | $7.45 | 0 | 3 | |
| Jensen Peder | director | 60000 0.029% | $7.45 | 4 | 0 | +3.75% |
| INGRAM ROBERT ALEXANDER | director | 48088 0.0232% | $7.45 | 1 | 0 | +118.24% |
| MONTGOMERY JOHN A | director | 46785 0.0226% | $7.45 | 0 | 1 | |
| Sniecinski Megan | Chief Business Officer | 45000 0.0217% | $7.45 | 1 | 0 | +118.24% |
| Erck Stanley C | director | 40000 0.0193% | $7.45 | 1 | 0 | +454.8% |
| Sheridan William P | Chief Medical Officer | 37954 0.0183% | $7.45 | 1 | 16 | +240.53% |
| LEE KENNETH B JR | director | 24252 0.0117% | $7.45 | 1 | 2 | +118.24% |
| Baker / Tisch Capital (GP), LLC | 10 percent owner | 17241 0.0083% | $7.45 | 3 | 3 | +289.09% |
| Grant Stuart | SR VP & CFO | 14717 0.0071% | $7.45 | 2 | 10 | +102.99% |
| McCullough David | VP | 13926 0.0067% | $7.45 | 0 | 4 | |
| Jones Michael L | Exec. Director, Finance - PAO | 10753 0.0052% | $7.45 | 0 | 3 | |
| SANDERS CHARLES A | director | 7000 0.0034% | $7.45 | 2 | 0 | <0.0001% |
| ALEXANDER W JAMES | SR. VP, Chief Medical Officer | 3659 0.0018% | $7.45 | 2 | 0 | <0.0001% |
| DARWIN MICHAEL A | Principal Accounting Officer | 3048 0.0015% | $7.45 | 2 | 2 | <0.0001% |
| HOROVITZ ZOLA P | director | 3000 0.0014% | $7.45 | 0 | 4 | |
| SEIDENBERG BETH C | director | 3000 0.0014% | $7.45 | 1 | 0 | <0.0001% |
| RIGGS RANDALL B | Senior VP Business Development | 1928 0.0009% | $7.45 | 2 | 1 | <0.0001% |
| Nugent Jonathan M | VP Corp Communications | 508 0.0002% | $7.45 | 2 | 1 | <0.0001% |
| Mills Mike | Principal Accounting Officer | 0 0% | $7.45 | 0 | 4 | |
| ABERCROMBIE GEORGE B | 0 0% | $7.45 | 2 | 8 | +230.41% | |
| Powell Lynne | Senior VP - CCO | 0 0% | $7.45 | 0 | 15 |
Institutional Investor Ownership
| BlackRock | $93.68M | 8.94 | 18.44M | -1.29% | -$1.22M | <0.01 | |
| The Vanguard Group | $89.8M | 8.57 | 17.68M | -0.49% | -$441,721.24 | <0.01 | |
| State Street | $88.78M | 8.47 | 17.48M | +36.79% | +$23.88M | <0.01 | |
| Avoro Capital Advisors Llc | $66.29M | 6.32 | 13.05M | 0% | +$0 | 0.79 | |
| Baker Bros Advisors LP | $51.44M | 4.91 | 10.13M | 0% | +$0 | 0.37 | |
| Kynam Capital Management Lp | $33.16M | 3.16 | 6.53M | +41.9% | +$9.79M | 0.42 | |
| Deerfield Management | $25.37M | 2.42 | 5M | +10.03% | +$2.31M | 0.06 | |
| Geode Capital Management | $22.36M | 2.13 | 4.4M | +3.28% | +$709,433.99 | <0.01 | |
| Alkeon Capital Management Llc | $20.83M | 1.99 | 4.1M | +145.55% | +$12.34M | 0.12 | |
| RP Management LLC | $19.54M | 1.86 | 3.85M | 0% | +$0 | 10.85 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $17.76M | 1.69 | 3.5M | +6.91% | +$1.15M | 0.46 | |
| GW&K Investment Management | $17.55M | 1.67 | 3.45M | +47.75% | +$5.67M | 0.16 | |
| Braidwell Lp | $17.17M | 1.64 | 3.38M | -40.9% | -$11.88M | 0.97 | |
| Fisher Asset Management Llc | $14.65M | 1.4 | 2.88M | +<0.01% | +$254.00 | 0.01 | |
| Nuveen | $13.31M | 1.27 | 2.62M | -24.43% | -$4.3M | <0.01 | |
| Two Sigma Advisers LP | $12.56M | 1.2 | 2.47M | +9.06% | +$1.04M | 0.02 | |
| Ameriprise Financial | $11.86M | 1.13 | 2.34M | +92.52% | +$5.7M | <0.01 | |
| Citigroup | $11.56M | 1.1 | 2.27M | +90.52% | +$5.49M | 0.01 | |
| Rice Hall James & Associates, LLC | $10.93M | 1.04 | 2.15M | -2.08% | -$232,237.29 | 0.65 | |
| Morgan Stanley | $10.2M | 0.97 | 2.01M | -35.98% | -$5.73M | <0.01 | |
| Goldman Sachs | $9.78M | 0.93 | 1.93M | +8.49% | +$765,103.86 | <0.01 | |
| Stifel | $9.37M | 0.89 | 1.84M | <0.01% | -$604.52 | 0.01 | |
| Fidelity Investments | $9.32M | 0.89 | 1.84M | -32.43% | -$4.47M | <0.01 | |
| Millennium Management LLC | $9.3M | 0.89 | 1.83M | +9.19% | +$782,254.00 | 0.01 | |
| Northern Trust | $9.17M | 0.88 | 1.81M | -2.25% | -$211,282.30 | <0.01 | |
| Segall Bryant & Hamill | $8.89M | 0.85 | 1.75M | +0.58% | +$51,465.48 | 0.17 | |
| Charles Schwab | $8.8M | 0.84 | 1.73M | +8.62% | +$697,824.34 | <0.01 | |
| Point72 Asset Management | $8.21M | 0.78 | 1.62M | New | +$8.21M | 0.01 | |
| Renaissance Technologies | $8.08M | 0.77 | 1.59M | -9.38% | -$836,154.50 | 0.01 | |
| Two Sigma | $8M | 0.76 | 1.57M | -33.04% | -$3.95M | 0.01 | |
| Rafferty Asset Management Llc | $7.97M | 0.76 | 1.57M | +64.27% | +$3.12M | 0.02 | |
| Eversept Partners LP | $7.28M | 0.69 | 1.43M | -6.32% | -$490,829.59 | 0.56 | |
| Prosight Management Lp | $7.11M | 0.68 | 1.4M | -37.28% | -$4.23M | 1.98 | |
| Bank of America | $6.94M | 0.66 | 1.37M | -3.81% | -$274,965.15 | <0.01 | |
| Jane Street Capital | $5.67M | 0.54 | 1.12M | +35.69% | +$1.49M | 0.01 | |
| Susquehanna International Group | $5.67M | 0.54 | 1.12M | +233.55% | +$3.97M | 0.01 | |
| Sarissa Capital Management LP | $5.56M | 0.53 | 1.09M | +9.42% | +$478,373.40 | 0.97 | |
| Voya Investment Management LLC | $5.08M | 0.48 | 999,316 | +20.89% | +$877,349.93 | 0.01 | |
| UBS | $5.06M | 0.48 | 996,555 | +45.48% | +$1.58M | <0.01 | |
| Voloridge Investment Management, LLC | $4.92M | 0.47 | 967,722 | -10.53% | -$578,733.95 | 0.02 | |
| Tang Capital Management, LLC | $4.06M | 0.39 | 800,000 | 0% | +$0 | 0.02 | |
| Caligan Partners LP | $3.85M | 0.37 | 758,502 | New | +$3.85M | 1.02 | |
| Advisor Group Holdings Inc | $3.81M | 0.36 | 750,694 | +8.32% | +$292,938.24 | 0.01 | |
| Deutsche Bank | $3.8M | 0.36 | 748,794 | -27.02% | -$1.41M | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $3.65M | 0.35 | 719,442 | +4.01% | +$140,939.51 | 0.01 | |
| DAFNA Capital Management, LLC | $3.6M | 0.34 | 709,500 | 0% | +$0 | 0.09 | |
| BNY Mellon | $3.5M | 0.33 | 689,708 | -8.28% | -$316,367.19 | <0.01 | |
| Alphacentric Advisors Llc | $3.43M | 0.33 | 675,000 | 0% | +$0 | 0.15 | |
| Qube Research & Technologies | $3.39M | 0.32 | 667,394 | -35.11% | -$1.83M | <0.01 | |
| Panagora | $3.21M | 0.31 | 632,559 | -5.46% | -$185,460.66 | 0.02 |